BEATING CANCER IS IN OUR BLOOD.

A NEW BREED OF CANCER NON-PROFIT

Driving Research Accelerating Cures

LEUKEMIA & LYMPHOMA SOCIETY®
OUR MISSION


Provide patients and families with hope, guidance, education and **SUPPORT**

Drive **ADVOCACY** for policies that protect patient access to lifesaving treatment

Fund **RESEARCH** to advance lifesaving treatments
LLS serves all blood cancers

15% leukemia
34% lymphoma
51% myeloma

176,000 new cases/yr

Blood cancer impact

Every 3 minutes someone is diagnosed with blood cancer

Blood cancers are the 3rd leading cause of cancer death in the US

More than 33% of blood cancer patients do not survive five years after diagnosis
# 2017 & 2018 FDA Approvals for Blood Cancers

LLS helped advance 34 of the 39 blood cancer treatments approved by the FDA in 2017 and 2018.

<table>
<thead>
<tr>
<th>Acute Lymphoblastic Leukemia</th>
<th>Acute Myeloid Leukemia</th>
<th>Chronic Lymphocytic Leukemia</th>
<th>Chronic Myeloid Leukemia</th>
<th>Hodgkin Lymphoma</th>
<th>Non-Hodgkin Lymphoma</th>
<th>Myeloma</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>calaspargase pegol-mkni * (Asparlas®)</td>
<td>gliteritinib * (Xospata®)</td>
<td>duvelisib * (Copiktra®) also approved for small cell lymphocytic lymphoma and follicular lymphoma</td>
<td>nilotinib (Tasigna®) for PH+ pediatric chronic myeloid leukemia</td>
<td>pembrolizumab (Keytruda®)</td>
<td>brentuximab vedotin (Adcetris®) for peripheral T-cell lymphoma</td>
<td>sisagenleucel (Kymriah®)</td>
<td>carfilzomib (Kyprolis®) for hairy cell leukemia</td>
</tr>
<tr>
<td>blinatumomab (Blinicyt®) for minimal residual disease positive ALL</td>
<td>glasdegib * (Daunirax®)</td>
<td>venetoclax (Venclexta®) also approved for small cell lymphocytic leukemia</td>
<td>bostinib (Bosulif®)</td>
<td>pembrolizumab (Keytruda®)</td>
<td>brentuximab vedotin (Adcetris®)</td>
<td>daratumumab (Darzalex®)</td>
<td>moxetumomab pasudotox * (Lumozi®)</td>
</tr>
<tr>
<td>tisagenleucel (Kymriah®)</td>
<td>ivosidenib * (Tibsovo®)</td>
<td>dasatinib (Sprycel®) for PH+ pediatric chronic myeloid leukemia</td>
<td>mogamulizumab * (Potelge®)</td>
<td>pembrolizumab (Keytruda®)</td>
<td>isatuximab vedotin (Adcetris®) for two rare subtypes of cutaneous T-cell lymphoma</td>
<td>ibritinib (Imbruvica®) for graft versus host disease</td>
<td></td>
</tr>
<tr>
<td>inotuzumab ozogamicin * (Besponsa®)</td>
<td>arsenic trioxide (Trisenox®)</td>
<td>axicabtagene ciloleucel * (Yescarta®)</td>
<td>axalabrutinib (Calquence®)</td>
<td>brentuximab vedotin (Adcetris®)</td>
<td>obinutuzumab (Gazyva®)</td>
<td>tagraxofusp (Elzonal®) for blastic plasmacytoid dendritic cell neoplasm</td>
<td></td>
</tr>
<tr>
<td>blinatumomab (Blinicyt®)</td>
<td>venetoclax (Venclexta®)</td>
<td>axicabtagene ciloleucel * (Yescarta®)</td>
<td>brentuximab vedotin (Adcetris®)</td>
<td>rituximab (Rituxan Mylera®) also approved for chronic lymphocytic leukemia</td>
<td>rituximab hyaluronidase (Rituxan Hybrala®) also approved for chronic lymphocytic leukemia</td>
<td>ibritinib (Imbruvica®) for Erstfeld-Chatler disease</td>
<td></td>
</tr>
<tr>
<td>enasidenib * (Idhifa®)</td>
<td>midostaurin * (Rydapt®)</td>
<td>acalabrutinib (Calquence®)</td>
<td>brentuximab vedotin (Adcetris®)</td>
<td>brentuximab vedotin (Adcetris®)</td>
<td>copanlisib * (Alqora®)</td>
<td>vemurafenib (Zelboraf®) for Erstfeld-Chatler disease</td>
<td></td>
</tr>
<tr>
<td>daunorubicin and cytarabine (Vyxeos®)</td>
<td>daunorubicin and cytarabine (Vyxeos®)</td>
<td>brentuximab vedotin (Adcetris®)</td>
<td>obinutuzumab (Gazyva®)</td>
<td>rituximab (Rituxan Mylera®) also approved for chronic lymphocytic leukemia</td>
<td>brentuximab vedotin (Adcetris®) for peripheral T-cell lymphoma</td>
<td>rituximab hyaluronidase (Rituxan Mylera®) also approved for chronic lymphocytic leukemia</td>
<td></td>
</tr>
<tr>
<td>gemtuzumab ozogamicin (Mylotarg®)</td>
<td>gemtuzumab ozogamicin (Mylotarg®)</td>
<td>daunorubicin and cytarabine (Vyxeos®)</td>
<td>brentuximab vedotin (Adcetris®)</td>
<td>obinutuzumab (Gazyva®)</td>
<td>rituximab hyaluronidase (Rituxan Mylera®) also approved for chronic lymphocytic leukemia</td>
<td>brentuximab vedotin (Adcetris®) for peripheral T-cell lymphoma</td>
<td></td>
</tr>
</tbody>
</table>

* Supported by The Leukemia & Lymphoma Society  
* New therapy  
■ Approved in 2018  
■ Approved in 2017  
† T-cell immunotherapy

Note: all other therapies were approved as new indications, reformulations of other therapies, new dosing schedules or in combination with another therapy.
LLS Research focuses on discovering and developing therapies to positively impact care for blood cancer patients.

- Research Grant Programs
- Therapy Acceleration Program®
- Beat AML® Initiative

Discovery → Development → Service to Patients
TAP progress to date

- >60 projects / >$115 M invested
- 16 active programs
- 3 FDA-Approved Therapies
  - Vyxeos (AML)
  - Yescarta (DLBCL, tFL, PMBCL)
  - Elzonris (BPDCN)
Beat AML Master Clinical Trial - a demonstration project designed to:

- **Disrupt** the landscape of clinical development
- Design clinical trials that are **for patients**
- **Change** the paradigm of treatment: precision medicine
- **Accelerate** drug registration for first-line AML treatment
Beat AML Master Trial approach

AML Patients → Genetic Sequencing

Computational Analysis → Clinical Trial
Collaboration is key
The Impact

Beat AML has changed how cancer drugs are developed!

- Making precision medicine a reality for patients
- New model for clinical trials: testing 9 drugs simultaneously
- Pushing the boundaries of technology: FDA-ready in real time
- Reducing costs 25-30%
- Setting collaboration as the new standard
- Accelerating timeline for drug approvals
BEATING CANCER IS IN OUR BLOOD.

A NEW BREED OF CANCER NON-PROFIT

Driving Research
Accelerating Cures

LEUKEMIA & LYMPHOMA SOCIETY®
Alignment of FY18 Research Commitments with Disease Severity & Incidence

LLS Spend $M

5 Yr Survival

AML
NHL-A
MM
MDS
ALL
CML
CLL
HL
NHL-I

Annual Incidence
Incidence Scale
25K
5K